Back to top
more

Fate Therapeutics (FATE)

(Delayed Data from NSDQ)

$4.30 USD

4.30
2,273,158

-0.24 (-5.29%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $4.30 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for FATE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Fate Therapeutics, Inc. [FATE]

Reports for Purchase

Showing records 101 - 120 ( 425 total )

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

12/14/2021

Company Report

Pages: 9

ASH Presentations on NK Therapy on Lymphoma

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

12/12/2021

Industry Report

Pages: 21

ASH 2021 Day 1 Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

12/10/2021

Industry Report

Pages: 10

HEALTHCARE- The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

12/06/2021

Industry Report

Pages: 10

HEALTHCARE -The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

12/01/2021

Daily Note

Pages: 8

Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

11/18/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

11/16/2021

Industry Report

Pages: 46

SITC 2021: Covered Companies Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

11/16/2021

Daily Note

Pages: 5

We Continue to Wait Our Fate in Solid Tumors

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

11/15/2021

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

11/14/2021

Company Report

Pages: 5

NK Cell Engager Improved FT538 Tumor Killing in a Solid Tumor Model

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 5.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

11/12/2021

Industry Report

Pages: 13

2021 Abstract Roundup For Covered CompaniesThis report contains brief updates on the following: ACET, ALPN, ANAB, BCEL, BEAM, CDAK, CTMX, FATE, IGMS, MRSN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

11/05/2021

Company Report

Pages: 7

3Q21: A Busy Year-End with Data in Two Conferences. PT to $60 for "Modest" Expectation in Solids

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

11/05/2021

Daily Note

Pages: 7

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

11/05/2021

Daily Note

Pages: 22

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

11/05/2021

Company Report

Pages: 7

Awaiting a FATE-ful ASH Update

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

11/05/2021

Industry Report

Pages: 13

Relevant Abstracts at Upcoming ASH Meeting

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

10/29/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

10/07/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

10/06/2021

Daily Note

Pages: 4

Solid Tumor Trial Posted on clinicaltrials.gov for Engineered NK Construct

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 5.00

Research Provided by a Third Party

Company: Fate Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

10/01/2021

Industry Report

Pages: 7

SITC 2021 Abstract Titles for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party